A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model

Cancer Res. 2000 Mar 1;60(5):1197-201.


The single biggest challenge now facing drug delivery (for liposomes and indeed other carriers) is to initiate and produce release of the encapsulated drug only at the diseased site and at controllable rates. Our efforts have focused on developing a new thermal-sensitive drug delivery system, specifically for the local control of solid tumors. We describe here a new lipid formulation containing doxorubicin that has been optimized for both mild hyperthermic temperatures (39 degrees C to 40 degrees C) that are readily achievable in the clinic and rapid release times of drug (tens of seconds). This new liposome, in combination with mild hyperthermia, was found to be significantly more effective than free drug or current liposome formulations at reducing tumor growth in a human squamous cell carcinoma xenograft line (FaDu), producing 11 of 11 complete regressions lasting up to 60 days posttreatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Drug Carriers
  • Drug Delivery Systems*
  • Humans
  • Hyperthermia, Induced
  • Liposomes
  • Mice
  • Neoplasms, Experimental / drug therapy*
  • Temperature


  • Antineoplastic Agents
  • Drug Carriers
  • Liposomes